Stephen Ewald Sells 16,349 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Medpace Stock Performance

NASDAQ:MEDP opened at $445.59 on Wednesday. Medpace Holdings, Inc. has a 52-week low of $293.20 and a 52-week high of $628.92. The stock has a fifty day moving average of $457.28 and a 200 day moving average of $512.30. The firm has a market capitalization of $12.73 billion, a price-to-earnings ratio of 28.01, a P/E/G ratio of 2.29 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the firm posted $3.67 EPS. The company’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, the Schall Law Firm, and others, are urging investors to act on a securities class action against Medpace tied to purchases made between April 22, 2025 and February 9, 2026. The repeated deadline reminders keep legal overhang and potential litigation costs in focus. Article: Pomerantz investor alert on Medpace class action
• Negative Sentiment: The legal campaign may raise concerns about possible damages, reputational pressure, and management distraction, which can act as a headwind for the shares until the lawsuit situation becomes clearer. Article: Rosen deadline reminder for Medpace investors
• Neutral Sentiment: Medpace General Counsel Stephen P. Ewald disclosed the sale of 16,349 shares at $450 each. Insider selling can attract investor attention, but one transaction does not necessarily indicate a broader operational issue. Article: SEC Form 4 filing for Stephen P. Ewald

Institutional Trading of Medpace

Hedge funds have recently added to or reduced their stakes in the business. Optiver Holding B.V. purchased a new stake in Medpace during the third quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the fourth quarter worth about $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Quarry LP purchased a new stake in Medpace during the 3rd quarter valued at about $35,000. Finally, Bayban purchased a new stake in Medpace during the 4th quarter valued at about $44,000. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on MEDP. Barclays lowered their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Robert W. Baird lowered their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Leerink Partners dropped their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a report on Friday, February 13th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.